当前位置: X-MOL 学术J. Infect. Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Development of Hepatocellular Carcinoma by Patients Aged 75-84 with Chronic Hepatitis C Treated with Direct-acting Antivirals.
The Journal of Infectious Diseases ( IF 6.4 ) Pub Date : 2020-06-25 , DOI: 10.1093/infdis/jiaa359
Eiichi Ogawa 1 , Hideyuki Nomura 2, 3 , Makoto Nakamuta 4 , Norihiro Furusyo 1, 5 , Eiji Kajiwara 6 , Kazufumi Dohmen 7 , Akira Kawano 8 , Aritsune Ooho 9 , Koichi Azuma 10 , Kazuhiro Takahashi 11 , Takeaki Satoh 12 , Toshimasa Koyanagi 13 , Yasunori Ichiki 14 , Masami Kuniyoshi 15 , Kimihiko Yanagita 16 , Hiromasa Amagase 17 , Chie Morita 18 , Rie Sugimoto 19 , Masaki Kato 20 , Shinji Shimoda 21 , Jun Hayashi 22 ,
Affiliation  

Direct-acting antiviral (DAA) treatment has revolutionized hepatitis C virus care. We aimed to evaluate the risk for the development of hepatocellular carcinoma (HCC) by patients aged 75-84 with chronic hepatitis C (CHC) following HCV elimination.

中文翻译:

接受直接作用抗病毒药物治疗的 75-84 岁慢性丙型肝炎患者肝细胞癌的发展。

直接抗病毒 (DAA) 治疗彻底改变了丙型肝炎病毒治疗。我们旨在评估 75-84 岁慢性丙型肝炎 (CHC) 患者在消除 HCV 后发生肝细胞癌 (HCC) 的风险。
更新日期:2020-06-27
down
wechat
bug